Compare Moderna, Inc. (MRNA) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Banco Santander SA — how do they compare? Moderna, Inc. trades at $220.35 (market cap $78.65B), while Banco Santander SA trades at $13.47 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 2.5× Moderna, Inc.'s market cap, and Banco Santander SA pays a 2.06% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Banco Santander SA for 55 Days on average.
| MRNA | SAN | |
|---|---|---|
Market Cap | $78.65B | $192.86B |
Volume | 37,373,437 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $203.46 | $15.05 |
52-Week Low | $22.36 | $9.65 |
Typical Hold Time | 59 Days | 55 Days |
Enterprise Value | $74.80B | $360.86B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Banco Santander (SAN) trades at $13.44, down 1.65% today amid bearish technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q2 missing. Fundamentals remain solid with 26.25% net income margin and 16.07% ROE, though cash flow trends show recent weakness. Recent developments include the completed Webster acquisition expanding U.S. presence and record Q2 2026 profits driven by digital transformation.
SAN presents a value opportunity with reasonable P/E of 13.55 and strong analyst support (64% buy ratings), but faces risks from declining operating cash flows and high debt levels. The technical bearish signal suggests near-term pressure, while fundamental strength supports long-term potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
